210 related articles for article (PubMed ID: 20570888)
1. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.
Tomihari M; Chung JS; Akiyoshi H; Cruz PD; Ariizumi K
Cancer Res; 2010 Jul; 70(14):5778-87. PubMed ID: 20570888
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.
Chung JS; Dougherty I; Cruz PD; Ariizumi K
J Immunol; 2007 Nov; 179(9):5778-84. PubMed ID: 17947650
[TBL] [Abstract][Full Text] [Related]
3. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.
Chung JS; Bonkobara M; Tomihari M; Cruz PD; Ariizumi K
Eur J Immunol; 2009 Apr; 39(4):965-74. PubMed ID: 19350579
[TBL] [Abstract][Full Text] [Related]
4. DC-HIL is a negative regulator of T lymphocyte activation.
Chung JS; Sato K; Dougherty II; Cruz PD; Ariizumi K
Blood; 2007 May; 109(10):4320-7. PubMed ID: 17284525
[TBL] [Abstract][Full Text] [Related]
5. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
[TBL] [Abstract][Full Text] [Related]
6. The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.
Chung JS; Tamura K; Akiyoshi H; Cruz PD; Ariizumi K
J Immunol; 2014 Mar; 192(6):2576-84. PubMed ID: 24516197
[TBL] [Abstract][Full Text] [Related]
7. Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.
Akiyoshi H; Chung JS; Tomihari M; Cruz PD; Ariizumi K
J Immunol; 2010 Apr; 184(7):3554-61. PubMed ID: 20176742
[TBL] [Abstract][Full Text] [Related]
8. DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.
Chung JS; Tamura K; Cruz PD; Ariizumi K
J Invest Dermatol; 2014 Nov; 134(11):2784-2794. PubMed ID: 24936834
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-Derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-Lymphocytes from the Pre-Metastatic Niches.
Ramani V; Teshima T; Tamura K; Chung JS; Kobayashi M; Cruz PD; Ariizumi K
J Invest Dermatol; 2018 Nov; 138(11):2443-2451. PubMed ID: 29857071
[TBL] [Abstract][Full Text] [Related]
10. Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function.
Chung JS; Yudate T; Tomihari M; Akiyoshi H; Cruz PD; Ariizumi K
J Immunol; 2009 Oct; 183(8):5190-8. PubMed ID: 19794069
[TBL] [Abstract][Full Text] [Related]
11. The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.
Chung JS; Tomihari M; Tamura K; Kojima T; Cruz PD; Ariizumi K
Immunology; 2013 Feb; 138(2):173-82. PubMed ID: 23113638
[TBL] [Abstract][Full Text] [Related]
12. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K
Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749
[TBL] [Abstract][Full Text] [Related]
13. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.
Chung JS; Shiue LH; Duvic M; Pandya A; Cruz PD; Ariizumi K
Blood; 2011 Mar; 117(12):3382-90. PubMed ID: 21252093
[TBL] [Abstract][Full Text] [Related]
14. Soluble DC-HIL/Gpnmb Modulates T-Lymphocyte Extravasation to Inflamed Skin.
Ramani V; Chung JS; Ariizumi K; Cruz PD
J Invest Dermatol; 2022 May; 142(5):1372-1380.e5. PubMed ID: 34695414
[TBL] [Abstract][Full Text] [Related]
15. High intensity focused ultrasound enhances anti-tumor immunity by inhibiting the negative regulatory effect of miR-134 on CD86 in a murine melanoma model.
Yuan SM; Li H; Yang M; Zha H; Sun H; Li XR; Li AF; Gu Y; Duan L; Luo JY; Li CY; Wang Y; Wang ZB; He TC; Zhou L
Oncotarget; 2015 Nov; 6(35):37626-37. PubMed ID: 26485753
[TBL] [Abstract][Full Text] [Related]
16. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
17. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
19. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
20. INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinic-polycytidylic acid-stimulated accessory cells.
Kasamatsu J; Azuma M; Oshiumi H; Morioka Y; Okabe M; Ebihara T; Matsumoto M; Seya T
J Immunol; 2014 Nov; 193(10):5199-207. PubMed ID: 25320282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
